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Inhaled nitric oxideNitric oxide (NO) is a key signalling molecule in the regulation of cerebral blood ﬂow. This review summarises
current evidence regarding the role of NO in the regulation of cerebral blood ﬂow at rest, under physiological
conditions, and after brain injury, focusing on subarachnoid haemorrhage, traumatic brain injury, and ischaemic
stroke and following cardiac arrest.We also review the role of NO in the response to hypoxic insult in the developing
brain. NO depletion in ischaemic brain tissue plays a pivotal role in the development of subsequent morbidity and
mortality throughmicrocirculatory disturbance and disordered blood ﬂow regulation. NO derived from endothelial
nitric oxide synthase (eNOS) appears to have neuroprotective properties. However NOderived from inducible nitric
oxide synthase (iNOS)may have neurotoxic effects. Cerebral NOdonor agents, for example sodiumnitrite, appear to
replicate the effects of eNOSderivedNO, and therefore haveneuroprotective properties. This is true in both the adult
and immature brain.We conclude that these agents should be further investigated as targeted pharmacotherapy to
protect against secondary brain injury.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Nitric oxide (NO) is a gaseous molecule synthesised from L-arginine
by the enzyme nitric oxide synthase (NOS) (Stuehr and Grifﬁth, 1992).
It acts as a neurotransmitter and is a component of the signalling path-
ways that operate between cerebral blood vessels, neurons and glial
cells. Three isoforms of NOS exist: endothelial nitric oxide synthase
(eNOS), neuronal nitric oxide synthase (nNOS), and inducible nitric
oxide synthase (iNOS). Disruption to the NO pathway underlies many
of the mechanisms behind brain injury and NO produced from each of
the three isoforms inﬂuences the evolution of brain damage in different
ways (Toda et al., 2009). This article will explore the current evidence
surrounding the role of the NO signalling pathway and NOS isoforms
in the regulation of resting cerebral blood ﬂow and in the neuroprotec-
tive and pathophysiological processes that occur after injury. We will
also examine the potential formanipulation of this pathway as potential
treatment strategy.in 
 Nitric oxide synthase— expression and functions
Nitric oxide is derived from three isoforms of the enzyme NOS. The
different sites of expression and activity of these enzymes play a critical
role in the differing functions of NO.
eNOS is expressed in the vascular endothelium and choroid plexus.
NO derived from eNOS (eNOS-NO) plays a role in preserving and main-
taining the brain's microcirculation (Toda et al., 2009), inhibiting plate-
let aggregation, leukocyte adhesion and migration (Broos et al., 2011),
and reducing smooth muscle proliferation (Toda et al., 2009).
nNOS is expressed in neuronal cell bodies and NO derived from
nNOS (nNOS-NO) acts as an important neurotransmitter associated
with neuronal plasticity, memory formation, regulation of central ner-
vous system blood ﬂow, transmission of pain signals and neurotrans-
mitter release (SchumanandMadison, 1994; Toda andOkamura, 2003).
iNOS is expressed in macrophages, glial cells and tumour cells in re-
sponse to pro-inﬂammatory cytokines or endotoxin (Marletta, 1988)
and unlike eNOS and nNOS it is not expressed unless induced by cyto-
kines or other agents. It can produce a large amount (100–1000 times
greater) of NO in relation to eNOS and nNOS (Pautz et al., 2010), due
to its independence from calcium dependent mechanisms for activa-
tion. After induction, iNOS continuously produces NO until the enzyme
is degraded (MacMicking et al., 1997).Ce
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Fig. 1. Inhibition of NO synthesis results in right shift of hypotensive portion of cerebral
autoregulatory curve. Cerebral autoregulation maintains an adequate and stable cerebral
blood ﬂow in the face of changes in mean arterial pressure (ﬂat portion of the curve).
The brain becomes vulnerable to ischaemia when cerebral blood ﬂow falls below 20 ml/
100 g/min (red dashed line). NOS inhibition results in right shift of the hypotensive
portion of the autoregulatory curve, resulting in the brain becoming susceptible to ischae-
mia at higher perfusion pressures. Therefore NO signalling is essential in maintaining
adequate cerebral blood ﬂow under conditions of ﬂuctuating mean arterial pressure.Role of NO in regulation of cerebral blood ﬂow
The brain accounts for 20% of the body's energy consumption
despite only accounting for 2% of its mass. One of the major roles of
the cerebral circulation is to supply oxygen to the brain tissues as
neuronal activation requires large amounts of energy to regulate the
ion ﬂuxes that occur on depolarisation. Therefore, it is essential that
cerebral blood ﬂow (CBF) is tightly regulated.
The NO signalling pathway plays a major role in the regulation of
CBF at rest and during physiological and pathological stresses. Under-
standing the mechanisms behind the regulation of these processes
may therefore give useful insights into the CBF changes that occur
during cerebral injury.
Twomainmechanismsunderlie the regulation of CBF at rest, autoreg-
ulation andneurovascular coupling. eNOS-NOplays a key role in autoreg-
ulation, whereas nNOS derived NO appears crucial for neurovascular
coupling.Autoregulation
Autoregulation is the mechanism by which a consistent supply of
blood to the brain tissues in the face of changing cerebral perfusion
pressure (CPP) is maintained. eNOS derived NO is essential for extend-
ing the lower limit of autoregulation. This is demonstrated by a right
shift of the autoregulation curve in eNOS knockout mice at low perfu-
sion pressures (Huang et al., 1996) (see Fig. 1). Elevation of CBF near
the lower limit of autoregulation and an increase in the hypotensive
portion of the autoregulatory curve are also NO dependent (Jones
et al., 2003). During pathological processes where CBF is reduced, such
as subarachnoid haemorrhage or ischaemic stroke, NO depletion could
therefore further exacerbate decreased ﬂow conditions and increase
the likelihood of permanent neuronal damage.
Neurovascular coupling
Neurovascular coupling is the process by which increased neuronal
activity is linked to the local regulation of CBF. This ensures that the
supply of oxygen is always greater than the demand, and is also
known as functional hyperaemia. It is achieved via an integrated action
of neurons, glial cells and blood vessels that form a ‘neurovascular unit’
(Attwell et al., 2010). Several signalling pathways exist tomediate ﬂow/
metabolismcoupling in this unit, and these interact onmultiple levels to
ensure a coordinated blood ﬂow response.
Disruption to neurovascular coupling is a common process that
underlies many brain disease states (Girouard and Iadecola, 2006).
Studies where nNOS is knocked out or inhibited have shown a decrease
in neuronal activity related blood ﬂow by up to 90% in the cerebellum
(Akgoren et al., 1994), that is reversible in the presence of an exoge-
nously administered NO donor (Piknova et al., 2011). nNOS inhibition
in rats causes signiﬁcant attenuation of the cerebral bloodﬂow response
to forepaw stimulation, which is disproportionate to the degree of
attenuation of somatosensory evoked potentials (Stefanovic et al.,
2007), indicating disruption to neurovascular coupling.
Metabolic pathways activated by glutamate also play a key role via
activation of neuronal NMDA receptors (Attwell et al., 2010). This causes
an inﬂux of calcium that activates NOS, resulting in increased blood ﬂow.
Glutamate also stimulates prostaglandin and epoxyeicosatrienoic acid
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(Hamilton et al., 2010). This pathway can cause both vasoconstriction
and vasodilatation (Golanov and Reis, 1994). Under conditions of
NO depletion vasoconstriction is favoured via predominance of
20-hydroxyeicosatetraenoic acid (20-HETE) and decreased production
of vasodilatory epoxyeicosatrienoic acids (EETs). These pathways are
illustrated in Fig. 2.
NO and the cerebral blood ﬂow response during hypoxia
and hypercapnia
Hypoxia and hypercapnia are used as examples of physiological
stresses as alterations in tissue partial pressures of oxygen and carbon
dioxide are extremely common in critical illness following a brain insult
(Peers et al., 2007). The NO signalling pathway plays a central role in the
cerebral blood ﬂow response to these alterations. NO pathway dysfunc-
tion occurs after brain tissue ischaemia, causing dysregulation of these
normal physiological responses.
Hypoxia
Decreased arterial oxygen supply (hypoxia) increases the baseline
level of CBF in humans (Mintun et al., 2001). NO plays a role in both sig-
nalling this event and the CBF response (Ho et al., 2012). Nonselective
NOS inhibition abolishes the increased CBF response to hypoxia in rats
(Takuwa et al., 2010). The evidence for this in humans is more indirect,
but it has been demonstrated that exposure to hypoxia during adapta-
tion to high altitudes increases NO levels and high-altitude dwellers
such as Tibetans have increased circulatingNO levels (Beall et al., 2012).
Hypercapnia
The modulation of cerebral vascular tone in response to changes in
arterial partial pressure of carbon dioxide is known as chemoregulation,
and this processmay be viewed as oneof themain regulators of cerebral
vascular tone.
The cerebral vasodilatory response to hypercapnia is inhibited by
L-arginine analogues, which act by blocking the NO synthesis
pathway, and by NOS inhibitors (Wang et al., 1992; Kirkeby et al.,
2000). Cerebral vasodilatation in response to hypercapnia is reduced
after experimental traumatic brain injury in a rodent model andNeuron
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Fig. 2. Nitric oxide inhibits the production of key arachidonic acid-derived messengers. NO
vasodilating EET. Endothelial nitric oxide synthase (eNOS) can be activated by ﬂow-induced sh
bloodﬂow to the brain. NO= nitric oxide, NMDAR=NMDA receptor, PLA2= phospholipase A
glutamate receptor, and PGE2 = prostaglandin E2.
Adapted with permission from Attwell et al. Nature 468(7321): 232–43.exogenous NO acts to reverse this (Zhang et al., 2002), helping to
restore the normal physiological response.
A study on human cell cultures showed an increase inNOproduction
in response to increased CO2 levels (Fathi et al., 2011b). However, it is
likely that the in vivo response differs from the in vitro response, due
to multiple interactions of the NO pathway with other intracellular
signalling pathways within the neurovascular unit.
Both hypoxia and hypercapnia are common after a cerebral insult
due to decreased conscious levels that lead to hypoventilation. There-
fore, in the face of a focal brain injury, NO depletion leads to disruption
to the normal physiological response to alterations in oxygen and
carbon dioxide, further exacerbating neuronal damage. Restoration of
the normal adaptive response via replenishing cerebral NO levels may
be efﬁcacious at reducing secondary brain injury.
There is therefore a need for further investigation into the NO sig-
nalling pathway in a ‘whole brain’model in humans, to precisely elu-
cidate the speciﬁc mechanisms underlying the observed blood ﬂow
effects. Healthy volunteer studies examining the role for NO in the
CBF responses to hypoxia and hypercapnia would enable clariﬁca-
tion of the role of NO signalling during global disruptions to cerebral
physiology, while studies in patients with cerebral injury would en-
able the effects of NO signalling during the evolution of focal brain
pathology to be quantiﬁed.
The role of NO in the CBF response to disease
The NO signalling pathway inﬂuences the evolution of secondary
brain injury in multiple ways, dependent on site, mechanism
and timing of NO synthesis and concentration. NO has effects
both on the vasculature and on a cellular level, and interacts
with many other signalling pathways. This makes it difﬁcult to trans-
late results from animal models where conditions are tightly
controlled to the patient population where the evolution of injury
occurs unpredictably.
NO depletion
Relative NO depletion appears to occur in the early stages of cerebral
injury regardless of the aetiology, e.g. after traumatic brain injury (TBI),
subarachnoid haemorrhage (SAH), post-cardiac arrest and ischaemic
stroke (Cherian et al., 2000; Tuzgen et al., 2003; Ahn et al., 2004). This
occurs simultaneously with a reduction in blood ﬂow (Hlatky et al.,eN
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(Cherian and Robertson, 2003; Lundblad and Bentzer, 2007). This
indicates that disruption to NO signalling is part of a common patho-
physiological pathway that leads to the development of secondary
brain injury regardless of the mechanism of insult. NO depletion
appears to be central in particular to many of the abnormal processes
that occur after SAH.
SAH is usually caused by the rupture of a cerebral aneurysm located
in the circle of Willis (van Gijn et al., 2007). The decrease in cerebrospi-
nal ﬂuid (CSF) NO metabolites is seen within 10 min of SAH and this is
associated with vasoconstriction (Sehba et al., 2000). This is thought
to be secondary to destruction of NOS function by haemoglobin
(Tanishima, 1980; Reiter et al., 2002; Pluta, 2008). Decreased NO
bioavailability is also caused by cerebral NO reacting with superoxide
anions to produce peroxynitrite (ONOO) (Radi, 2013). Peroxynitrite
formation may cause damage to mitochondria, the vascular endotheli-
um and smooth muscle cells (Moro et al., 2005). In patients with SAH,
increased CSF levels of the endogenous NOS synthase inhibitor
asymmetric dimethylarginine (ADMA) were observed, and higher
levels predicted poorer long term outcome (Li et al., 2014). However,
another study showed a rise in CSF NO metabolites 24 h after SAH and
the higher the level the worse the outcome (Ng et al., 2001). The
discrepancies may be explained by the complexity surrounding the
biochemical pathways relevant to the generation and elimination of
NO and ADMA. An increase in NO metabolites is only an indirect
measure of NO levels (the short half life of NO making it difﬁcult to
measure directly), and gives no information regarding the source or
activity of the NO generated.
SAH is associated with microvascular constriction, resulting in
microthrombus formation (Sabri et al., 2012) and microinfarctions
(Stein et al., 2006). There is an associated global decrease in cerebral
NO levels and a corresponding increase in cerebral P-selectin levels
(Sabri et al., 2012). P-selectin is an endothelial cell adhesion molecule
that promotes platelet aggregation and ﬁbrin deposition (Zimmerman
et al., 1992). The inhibition of NO synthesis results in increased
P-selectin expression (Davenpeck et al., 1994), therefore NO depletion
favours microthrombosis formation.
Cortical spreading depression (CSD) consists of a wave of electroen-
cephalogram (EEG) silence moving across the cortical surface (Leao,
1944). CSDs play a role in both early brain injury (Nishizawa, 2013)
and in delayed cerebral ischaemia after SAH (Dreier et al., 2006),
as well as traumatic brain injury and stroke (Dreier, 2011). In healthy
brain tissue, spreading depolarisation is associated with vasodilatation.
However, in damaged brain tissue an inverse blood brain ﬂow response
occurs which results in vasoconstriction and tissue ischaemia (Dreier
et al., 2013). Reduced levels of NO render the brain more susceptible
to CSDs. Basal levels of NO determine the threshold of CSDs (Petzold
et al., 2008) and NO also acts to restore impaired cerebrovascular
reactivity after CSD (Scheckenbach et al., 2006).
Therefore it can be seen that NO signalling plays a crucial role in the
blood ﬂow changes that occur after subarachnoid haemorrhage. NO de-
pletion plays a major role in early brain injury, microthrombus forma-
tion and cortical spreading depression. Targeting this pathway may
enable partial restoration of physiological blood ﬂow, helping to prevent
secondary neuronal injury.
eNOS function
Impairment of eNOS activity is also implicated in many cellular
mechanisms of neuronal injury (Srivastava et al., 2012) and is seen
after SAH, TBI and ischaemic stroke. Innate eNOS activity determines
susceptibility to injury, with possession of isoformswith greater activity
conferring protection against secondary neuronal insult.
One of themajor causes of morbidity andmortality following SAH is
delayed cerebral ischaemia (DCI). This occurs in about 30% of patients
(Weir and MacDonald, 1993; Khurana and Besser, 1997) typicallybetween days 3 and 12 following SAH (Khurana and Besser, 1997).
Originally this was thought to be caused by ‘spasm’ of cerebral arteries
seen on CT angiography, but emerging evidence suggests that this is un-
likely to be directly causal (Rowland et al., 2012). Recently it has been
discovered that the NO signalling pathway plays a signiﬁcant role in
the pathogenesis of DCI (Vellimana et al., 2011). Genetic variation in
the eNOS gene in humans inﬂuences the risk of DCI after SAH, as posses-
sion of an isoform that results in lower eNOS activity results in greater
risk (Khurana et al., 2004; Starke et al., 2008).
eNOS activity is also important after TBI. The immunoreactivity of
eNOS is increased in the area surrounding the contused area in the
ﬁrst 3 days after experimental trauma (Cobbs et al., 1997). eNOS knock-
out mice have greater reduction in CBF than wild type variants in the
ﬁrst 2 h after trauma (Lundblad et al., 2009). Genetic variants of eNOS
inﬂuence the maintenance of CBF after severe TBI. As in SAH, patients
with decreased endogenous eNOS levels had poorer outcomes than
patients with alleles that did not affect eNOS levels (Robertson et al.,
2011).
This is also the case in ischaemic stroke. Stroke is most often caused
by a thrombotic or embolic blockage of a cerebral artery, causing inter-
ruption to blood ﬂow, ischaemia and tissue death. eNOS deﬁcient mice
have bigger infarcts than wild type after middle cerebral artery occlu-
sion in an animal model of ischaemic stroke (Huang et al., 1996).
eNOS uncoupling
Functional uncoupling of eNOS from its co-factor tetrahydrobiopterin
(BH4) also occurs after cerebral insult. eNOS uncoupling occurs under
ischaemic conditions, causing superoxide to be generated instead of NO
(Vasquez-Vivar et al., 1998; Stuehr et al., 2001). Superoxide reacts with
NO to formperoxynitrite, which is in itself a neurotoxin, decreasing levels
of bioactive NO (Wink et al., 1993; Pluta et al., 2001). This reduction inNO
bioavailability contributes further to secondary brain injury (Drexler and
Hornig, 1999; Cai and Harrison, 2000).
eNOS uncoupling contributes to injury after SAH (Sabri et al., 2011a)
and simvastatin acts to re-couple eNOS after SAH (Sabri et al., 2011b) in
an experimental blood injection model of SAH in rodents. This implies
that recoupling of eNOSmay be a promising therapeutic target. Howev-
er, a largemulticentre randomised phase 3 trial failed to detect any ben-
eﬁt in the use of simvastatin for long- or short-term outcome in patients
with aneurysmal SAH (Kirkpatrick et al., 2014). It is unclear why this
was the case but it is likely that pathological aneurysm rupture triggers
pathways that are not activated by a blood injection animal model,
therefore statinsmay not be acting in the same fashion as in experimen-
tal models. Another possibility is that eNOS uncoupling has metabolic
and cellular effects that affect other cellular signalling pathways, and
the physiological differences between rodents and humans render
results from animal studies difﬁcult to interpret. For example, eNOS
knockout appeared to confer neuroprotection in one study, indicating
that the detrimental effects of eNOS uncouplingmay outweigh the ben-
eﬁts of eNOS activity in this particular model (Sabri et al., 2013).
Ischaemia/reperfusion injury
This is a pathophysiological process responsible for organ injury in a
variety of conditions such as myocardial infarction, organ transplanta-
tion and cardiac arrest. NO plays a pivotal role in the development of
this condition, with NO donor agent administration reducing ischae-
mia/reperfusion (I/R) injury in animal models (Shiva et al., 2007). A
systematic review of NO donor administration during animal stroke
models demonstrated an overall improvement in cerebral blood ﬂow
and a decrease in infarction volume (Willmot et al., 2005). However,
whether these results translate into the patient population with cere-
bral I/R injury (e.g. ischaemic stroke, cardiac arrest) has not yet been
tested (Roberts et al., 2013) and represents an important area of future
research. It is also likely that many of the neuroprotective effects of NO
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ply the improvement of cerebral blood ﬂow.
Cardiac arrest and subsequent recovery result in complete interrup-
tion followed by restoration of blood supply, and thereforemay provide
the best clinical model of ischaemia/reperfusion. Inhaled NO and intra-
venous sodium nitrite (a NO donor) have been shown to confer neuro-
protection in mice and rats (Dezfulian et al., 2012; Ichinose, 2013), and
this appears to be mediated by S-nitrosation of proteins rather than the
canonical cyclic GMP signalling pathways (Dezfulian et al., 2012). eNOS
mediatedmechanisms are responsible for the neuroprotective effects of
therapeutic hypothermia after cardiac arrest, and inhaled NO conferred
neuroprotection in eNOS knockout mice, replicating the beneﬁcial
effects of hypothermia (Kida et al., 2014). Therefore, there is prelimi-
nary evidence for NO donors as a potential neurotherapeutic agent
after cardiac arrest.
The role of iNOS
It has been thought that NOderived from iNOS is responsible for some
of the neurotoxic actions of NO post-brain injury. One proposed mecha-
nism by which this occurs is via the reaction of iNOS generated NO with
superoxide generated from uncoupled eNOS to form peroxynitrite. The
putative mechanism behind this is illustrated in Fig. 3.
However, this is an oversimpliﬁed view, and it is more likely that
iNOS derived NO, like eNOS-NO, has several roles to play and that the
balance between neurotoxicity and neuroprotection is dependent on
many factors. As iNOS derived NO has multiple actions, results from an-
imal studies may be focusing on its effects on cerebral blood ﬂow
(which is an easily measurable outcome) without accounting for the
cellular and metabolic effects (which are more difﬁcult to quantify).
NO derived from iNOS appears to contribute to neurotoxicity after
ischaemic stroke, as animal knockout models have smaller infarcts
than their wild type counterparts (Iadecola et al., 1997). An increase
in NO above basal levels secondary to iNOS occurs 12–24 h after MCA
occlusion and contributes to neurotoxicity, with iNOS inhibition leading
to reduced infarct volume (Iadecola et al., 1995).
There is also evidence that NO produced by iNOS contributes to neu-
rotoxicity following TBI. iNOS expression is signiﬁcantly induced by
brain injury, with peak concentrations occurring around 1–2 days
after TBI (Clark et al., 1996; Wada et al., 1998). Patients with higher
levels went on to have a worse outcome (Tisdall et al., 2013). A recent
phase II clinical trial (NOSTRA) in TBI patients using the NOS inhibitor 4-
amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin (VAS203), which preferentiallyNeuroprotection 
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Fig. 3. Roles of NO and peroxynitrite in the pathophysiology of acute brain injury. Brain ischa
increases in endothelial NO generation, associated with neuroprotective actions. Ischaemic en
stimulated activity inducible NOS (iNOS) in astrocytes, microglia and inﬁltrating inﬂammator
such as TNFα and IFNβ, and cellular signalling pathways responsible for the response to hypox
of eNOS, mitochondrial dysfunction, and the stimulated activity of NADPH oxidase, xanthine o
damaging lipids, proteins and DNA that contributes signiﬁcantly to neurotoxicity.
Adapted with permission from Pacher P et al. Physiol Rev 2007; 87:31.inhibits iNOS(Terpolilli et al., 2009), showedsigniﬁcantly improvedextended
Glasgow Outcome Scores compared to placebo (Stover et al., 2014).
Data on the role of iNOS after TBI is conﬂicting. Attenuation of CBF at
72 h after TBI was demonstrated in iNOS knockout mice (Foley et al.,
2008), which also correlated with long-term functional outcome (Sinz
et al., 1999; Bayir et al., 2005). The inhibition of iNOS appeared to lead
to exacerbation of deﬁcits in cognitive performance and increased
neuron loss (Sinz et al., 1999). However, these studies are conﬁned to
rodent models of controlled cortical impact injury, and the CBF results
may be linked to pathological vasodilatation linked to inﬂammation.
Thismay explain the apparent contradictory results shown, and empha-
sises that simplymeasuring cerebral blood ﬂow does not give the entire
picture with regard to the effects of NO in the brain after injury. Overall,
the balance of evidence is in favour of iNOS activity being harmful in the
patient population, and therefore inhibition of destructive cascades
mediated via iNOS may have promise as a potential future therapy.
The role of NO signalling in the developing brain
Neonatal hypoxic–ischaemic insult is a major cause of acute mortal-
ity and is often associated with permanent neuropsychiatric problems,
presenting a major public health concern. There is a lack of speciﬁc
treatments besides hypothermia available for this condition; therefore
identiﬁcation and investigation of potential molecular therapeutic
targets are of utmost importance.
NO is involved in several critical processes in the developing brain,
including myelination (Olivier et al., 2010). It also plays a key role in
the immature brain's response to hypoxic–ischaemic insult. Inhaled
NO is neuroprotective in the developing brain, with reduction in the
size of excitotoxic and ischaemic lesions in rats (Pansiot et al., 2010;
Charriaut-Marlangue et al., 2012). Boosting NO-cGMP signalling using
sildenaﬁl, a phosphodiesterase type 5 inhibitor increases blood ﬂow
and has neuroprotective effects in the rat model of hypoxic–ischaemic
brain injury (Charriaut-Marlangue et al., 2014).
However, as in the developed brain, it appears that dosage and
timing of exposure to NO or molecules that inﬂuence the NO signalling
pathway are extremely important. InhaledNOgiven during the reperfu-
sion period appears to have neurotoxic effects (Charriaut-Marlangue
et al., 2012). This may be due to the activation of nNOS as inhibition
leads to improved CBF and perfusion early after reoxygenation (Hsu
et al., 2014). As in the developed brain, iNOS activation may be respon-
sible for damage in the late (N24 h) phase (Higuchi et al., 1998). There-
fore further work is needed to determine the optimal timing,Neurotoxicity 
eperfusion Hypoxia 
Oxidant stress 
Glutamate 
Ca2+ 
Cytokines 
OS 
ONOO-
O2-
XO 
COX-2 
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emia and reperfusion leads to stimulation of endothelial NOS (eNOS), resulting in brief
ergy depletion and oxidant production trigger the release of glutamate, which results in
y cells. iNOS activation also occurs in response to the release of inﬂammatory cytokines
ia. During the same period of time, superoxide production is enhanced due to uncoupling
xidase (XO), and cyclooxygenase-2 (COX-2). Formation of peroxynitrite is then favoured,
Table 1
A selection of pharmacological studies detailing the effects of NO donors on animal models of brain injury.
Study Model use Type of agent Dose Outcomes
Terpolilli et al. (2013) TBI; mice Inhaled NO 50 ppm Reduced lesion volume
Improved neurological function
Terpolilli et al. (2012) MCA occlusion; mice Inhaled NO 5–50 ppm Reduced infarct volume by 40%
Zhang et al. (1994) MCA occlusion; rats Intravenous SNP
Intravenous SIN 1
3 mg/kg/h
1.5–6 mg/kg/h
Reduction in infarct size
Morikawa et al. (1994) MCA occlusion; rats Intravenous L-arginine 300 mg/kg Reduced infarct volume by 35%
Jung et al. (2006) MCA occlusion; rats Intravenous sodium nitrite 48 and 480 nmol 33% and 77% reduction in infarct size
Reduced neurological deﬁcit
Li et al. (2013) MCA occlusion; mice Inhaled NO 10, 20, 40, 60 or 80 ppm Dose and duration dependent
reduction in infarct volume up to 50%
Fathi et al. (2011a) Subarachnoid blood
clot implantation; macaques
Intravenous sodium nitrite 300 μg/kg/h 26.9% reduction in vasospasm
Pluta et al. (2005) Subarachnoid blood
clot implantation; monkeys
Intravenous sodium nitrite 90 mg over 24 h Prevention of vasospasm development
SNP = sodium nitroprusside.
SIN 1 = 3-morpholino-sydnonimine.
240 P.S. Garry et al. / Experimental Neurology 263 (2015) 235–243concentration and duration of NO therapy, and translation of these
results to a human model is also needed.Current therapies
Despite the controversies surrounding NO dysfunction after brain
injury, there is animal evidence that increasing cerebral NO levels either
directly using inhaled NO or indirectly using NO donors has neuroprotec-
tive effects. Table 1 summarises a selection of these pharmacological
studies.Future perspectives
Manipulation of the NO synthesis pathway shows great promise as a
pharmacological therapeutic target. Exogenous NO appears to replicate
the actions of eNOS derived NO, without contributing to neurotoxicity.
NOdonorsmay be neuroprotective by preventingNOdepletion, helping
to normalize capillary blood ﬂow and improve oxygen delivery to the
tissue (Shiva, 2013). Cellularmechanisms such as S-nitrosylation of pro-
teins and effects on mitochondrial respiration also play an important
role (Dezfulian et al., 2012).Fig. 4. The nitrate–NO cycle. In normoxia NOS is functional and generates NO, which is oxidised
(ccox) and ceruloplasmin (Cp) to nitrite (NO2−). Nitrate is also derived from the diet aswell as th
is reduced to bioactive NO by a number of mammalian nitrite reductase enzymes including Hb
oxidase (SO), components of the mitochondrial electron transport chain (ETC.) and NOS.
Adapted with permission from Shiva S. Redox Biol 2013; 1(1): 40–44.However, themajority of this evidence has come from experimental
animal models, largely focussing on ischaemic stroke whereas SAH, TBI
and post-cardiac arrest are relatively under researched.
Cardiovascular instability when using classic NO donors such as glyc-
eryl trinitrate (GTN) and sodiumnitroprusside precludes their use in crit-
ically ill unstable patients, and makes results of drug trials difﬁcult to
interpret as local effects are negated by systemic blood pressure effects.
However, sodium nitrite is emerging as a feasible, safe NO donor
with minimal effects on the systemic vasculature in patients after SAH
(Pluta et al., 2011; Oldﬁeld et al., 2013). It has also been used safely in
cardiac arrest survivors (Dezfulian et al., 2012). This is because cerebral
tissue is able to convert endogenous nitrite toNOwithout the need for ox-
ygen as a substrate (van Faassen et al., 2009), meaning that when the tis-
sues are hypoxic (such as after cerebral injury) nitrite is only converted to
NO locally. The mechanisms underlying this are illustrated in Fig. 4.
The results from animal studies have been promising, with preven-
tion and reversal of cerebral vasospasm after experimental SAH (Pluta
et al., 2005; Fathi et al., 2011a). However, these are based on autologous
blood clot injection models, and as discussed previously pathological
aneurysm rupture is likely to activate multiple cellular signalling
pathways that may not be replicated in these experimental models.
Therefore large-scale clinical trials are needed to translate these results
to patients.by haemoglobin (Hb) andmyoglobin (Mb) to nitrate (NO3−) and by cytochrome c oxidase
e normoxic oxidation of nitrite by cytochrome P450 enzymes (CYP450). In hypoxia, nitrite
, Mb, neuroglobin (Ngb), xanthine oxidoreductase (XOR), aldehyde oxidase (AO), sulphite
241P.S. Garry et al. / Experimental Neurology 263 (2015) 235–243Conclusion
NO is an important mediator in the regulation of CBF in the resting
state, acting as a key modulator on the pathways responsible for
maintaining resting CBF and perfusion under physiological stresses
such as ﬂuctuations of blood pressure, hypoxia and hypercapnia. It
also plays a key role in the development of the healthy brain. Disruption
to NO synthesis andmetabolism underliesmany of the pathophysiolog-
ical processes that occur after brain injury, and appears to occur regard-
less of the mode of injury. The available evidence suggests that NO
derived from eNOS is neuroprotective after acquired brain injury
whereas NO synthesised by iNOS contributes to further damage, and
that this difference is due to differences in timing, spatial location and
concentration of NO generated by each isoform. This has led to investiga-
tion of drugs that inﬂuence NO signalling as potential therapeutic agents.
In particular, NO donors have been shown to be neuroprotective and
efﬁcacious in reducing secondary brain injury in animals, potentially by
replicating some of the effects of endogenous NO derived from eNOS.
iNOS inhibitors may also hold promise as a future neurotherapeutic
target. Future studies should focus on investigating the therapeutic
potential of the many other signalling molecules that interact with the
NO synthesis pathway and determining long-term side effects of NO
pathway manipulation in the injured brain. The hypotheses presented
in this reviewmust be tested in large-scale clinical trials to verify wheth-
er promising results from animal studies can translate into the patient
population. Better understanding of the role of the NO pathway may
lead to the development of exciting new pharmacotherapies designed
tominimise secondary brain injury,with the aimof reducing themorbid-
ity and mortality from devastating conditions such as subarachnoid
haemorrhage, ischaemic stroke, traumatic brain injury and neonatal
hypoxic–ischaemic insult.
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